All In Biotech

Drug Trial Radar · NCT06043817

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

345

Planned (sponsor's estimate)

Start

Sep 26, 2023

Primary completion

Dec 1, 2029

Study completion Dec 1, 2029

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.

Conditions

  • Non-Small Cell Lung Cancer
  • NSCLC
  • EGFR/HER2 Exon 20 Insertion Mutation

Interventions

  • STX-721/PFL-721 (Escalated)Drug

    STX-721/PFL-721 dose will be escalated per cBLRM-design.

  • STX-721/PFL-721 (3 dose levels)Drug

    Participants will receive STX-721/PFL-721 at one of three dose levels.

  • STX-721/PFL-721 (RP2D)Drug

    Participants will receive the RP2D of STX-721/PFL-721.

  • STX-721/PFL-721 (Escalated) with platinum-based chemotherapyDrug

    STX-721/PFL-721 in combination with platinum-based chemotherapy dose will be escalated per iBOIN-design.

  • STX-721/PFL-721 with platinum-based chemotherapyDrug

    Participants will receive STX-721/PFL-721 at dose selected in Part 1b in combination with platinum-based chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Dose Escalation (MTD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: 28 days
  2. Part 1 Dose Escalation (OBD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: 28 days
  3. Part 2 RP2D Selection: C(max) of STX-721/PFL-721Time frame: 1 year
  4. Part 2 RP2D Selection: AUC(0-inf) of STX-721/PFL-721Time frame: 1 year
  5. Part 2 RP2D Selection: AUC(0-t) of STX-721/PFL-721Time frame: 1 year
  6. Part 2 RP2D Selection: AUC(0-τ) of STX-721/PFL-721Time frame: 1 year
  7. Part 2 RP2D Selection: Number of participants with confirmed objective response rate (ORR) defined as the percentage of participants with partial response (PR) or complete response (CR) based on RECIST v1.1 per investigator assessment.Time frame: 1 year
  8. Part 3 Dose Expansion: Number of participants with confirmed ORR defined as the percentage of participants with PR or CR based on RECIST v1.1 per investigator assessment.Time frame: 1 year

Locations

32 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope

    Huntington Beach, California · Recruiting

  • City of Hope

    Irvine, California · Recruiting

  • Levine Cancer Institute - Charlotte

    Charlotte, North Carolina · Recruiting

  • Thomas Jefferson University Research Facility

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology Partners - PPDS

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Utah - Huntsman Cancer Institute - PPDS

    Salt Lake City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Chris O'Brien Lifehouse Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Institut Bergonie - PPDS

    Bordeaux, France · Recruiting

  • CHU de Lille - Hopital Claude Huriez

    Lille, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • AP-HM- Hôpital de La Timone

    Marseille, France · Recruiting

  • Institut Claudius Regaud - PPDS

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • EDOG Institut de Cancerologie de l'Ouest - PPDS

    Saint-Herblain, Loire-Atlantique, France · Recruiting

  • Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30

    Berlin, Germany · Recruiting

  • Universitätsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, Germany · Recruiting

  • Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

  • CHA Bundang Medical Center, CHA University

    Seongnam-si, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • START - Rioja Hospital Universitario San Pedro

    Logroño, La Rioja, Spain · Recruiting

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, Malaga, Spain · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.